Abstract

Introduction: The Endoscopic retrograde cholangiopancreatography (ERCP) is the main therapeutic procedure at the present time like complement of the minimally invasive surgery of the biliary tracts and of the pancreas, non-exempt of complications.

Aims: Show the level of competence and performance achieved in the treatment of 14,213 biliopancreatic diseases by ERCP during 25 years at the CNCMA.

Methods: Retrospective and descriptive study of 14,462 ERCP records taken from the database of the CNCMA, which were carried out from January 4, 1995 to February 5, 2020.

Results: Of 14,462 ERCP records, 14,213 they remained for analysis; 5,148 (38%) male and 8,224 (62%) female, ages 18 to 93 years; 4,548 (34%) diagnostic and therapeutic ERCPs were performed, 8,824 (66%). The primary indication was the study of jaundice in 8,690 (65%) and the main diagnosis was choledocholithiasis (5,799 patients [43%]), followed by malignant bile duct strictures (3,685 patients, [27%]). The most widely used intervention was endoscopic sphincterotomy (6,236) to remove stones (3,267), and the placement of prostheses in the bile duct was frequently followed (3,138). Complications occurred in 449 cases, 348 (4%) during 8824 therapeutic procedures and 101 (2.2%) in diagnoses. There was a mortality of 0.19% (28 patients), 24 (0.3%) in therapeutic procedures and four (0.08%) in diagnoses.

Conclusions: Our results demonstrate the high level of competence and performance achieved and the high diagnostic value and therapeutic success of ERCP, with minimal complications.

Keywords: Endoscopic Retrograde Cholangiopancreatography; Sphincterotomy; Choledocholithiasis

References

1. Aksentijevich I and Kastner DL. “Genetics of monogenic autoinflammatory diseases: past successes, future challenges”. Nature Reviews Rheumatology 7 (2011): 469-478.
2. Gulbuz Sezgin., et al. “The association of endoplasmic reticulum aminopeptidase-1 (ERAP-1) with Familial Mediterranean Fever (FMF)”. United European Gastroenterology Journal1 (2016): 92-96.
3. Daniels M., et al. “Familial mediterranean fever: high gene frequency among the non-askenazi jewish populations in Israel”. American Journal of Medical Genetics 55 (1995): 311-314.
4. Odabas AR., et al. “Familial mediterranean fever”. South Medical Journal12 (2002): 1400-1403.
5. Gershoni-Baruch R., et al. “Male sex coupled with articular manifestations cause a 4-fold increase in susceptibility to amyloidosis in patients with familial mediterranean fever homozygous for the M694V- MEFV mutation”. Journal of Rheumatology2 (2003): 308-312.
6. Zaks N., et al. “Analysis of the three most common MEFV mutations in 412 patients with familial mediterranean fever”. Israel Medical Association Journal (IMAJ) 8 (2003): 585-588.
7. Brik R., et al. “Familial mediterranean fever: clinical and genetic characterization in a mixed pediatric population of jewish and arap patiens”. Pediatrics 5 (1999): e70.
8. Konstantopoulos K., et al. “Familial mediterranean fever associated pyrin mutations in Greece”. Annals of the Rheumatic Diseases 5 (2003): 479-481.
9. Medlej HM., et al. “Genetic screening of fourteen mutations in jordanian familial mediterranean fever patients”. Human Mutation4 (2000): 384.
10. Tunca M., et al. “On behalf of the Turkish FMF Study Group. The results of a nationwide, multicenter analysis of the clinical and genetic characteristics of the Turkish FMF patients (abstract)”. Clinical and Experimental Rheumatology 20 (2002): S92.
11. Livneh A., et al. “Criteria for the diagnosis of familial mediterranean fever”. Arthritis Rheum10 (1997): 1879-1885.
12. Dig Giaglis S., et al. “Increased frequency of mutations in the gene responsible for familial Mediterranean fever (MEFV) in a cohort of patients with ulcerative colitis: evidence for a potential disease-modifying effect?” Digestive Diseases4 (2006): 687-692.
13. Fierabracci A., et al. “The putative role of endoplasmic reticulum aminopeptidases in autoimmunity: Insights from genomic-wide association studies”. Autoimmune Review (2012).
14. Saric T., et al. “An IFN-gamma-induced aminopeptidase in the ER, ERAP1, trims precursors to MHC class I-presented peptides”. Nature Immunology 3 (2002): 1169-1176.
15. Serwold T., et al. “ERAAP customizes peptides for MHC class I molecules in the endoplasmic reticulum”. Nature 419 (2002): 480-483.
16. Tanioka T., et al. “Human leukocyte-derived arginine aminopeptidase. The third member of the oxytocinase subfamily of aminopeptidases”. Journal of Biological Chemistry 278 (2003): 32275-32283.
17. York IA., et al. “The ER aminopeptidase ERAP1 enhances or limits antigen presentation by trimming epitopes to 8-9 residues”. Nature Immunology 3 (2002): 1177-1184.
18. Saveanu L., et al. “Concerted peptide trimming by human ERAP1and ERAP2 aminopeptidase complexes in the endoplasmic reticulum”. Nature Immunology 6 (2005): 689-697.

Citation

Citation: Raúl A Brizuela Quintanilla., et al. “Treatment of Biliopancreatic Diseases by Endoscopic Retrograde Cholangiopancreatography. Retrospective Analysis of Twenty-five Years in a Tertiary Reference Center". Acta Scientific Gastrointestinal Disorders 3.12 (2020): 11-16.

Copyright

Copyright: © 2020 Raúl A Brizuela Quintanilla., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.